Clinical Trial Update: JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating JK-1201I in combination with adjuvant temozolomide for newly diagnosed glioblastoma multiforme; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• JK-1201I
• Temozolomide (Temozolomide)

Snippet

Sponsor: JenKem Technology Co., Ltd. | Conditions: Glioblastoma Multiforme (GBM) | Phase 2 | Status: RECRUITING